Skip to content
Screener

Assembly Biosciences ASMB Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue$13.4MBeat by $4.8M
EPS-$0.20Beat by $0.52
Revenue estimate$8.6M
EPS estimate-$0.72
“During the second quarter, we advanced several important strategic priorities, including expanding ABI-6250 into cholestatic liver diseases and strengthening our balance sheet through a successful financing to support the continued advancement of our pipeline. We were also pleased to receive Gilead's clinical development plan for the HSV helicase primase inhibitor program, which includes plans for GS-1179 to advance into a Phase 2 clinical trial by the end of 2026. The plan also contemplates evaluation of GS-1179 across broader prevention settings, including in connection with HIV PrEP, further reinforcing the potential opportunity for this program. We expect to make our determination on whether to opt-in to the U.S. cost and profit share soon after we receive the commercial cost estimates from Gilead, which will complete the opt-in package.”
Jason Okazaki

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$9.1M
EPS estimate-$0.66

Financials

Q2 2026

Income statement

See full
Revenue$13.4M+38.9%
Operating income-$6.3M+42.8%
Net income-$3.9M+62.2%
EPS (diluted)-$0.20+85.0%

Balance sheet

See full
Cash & equivalents$32.3M+34.5%
Total debt$2.4M-18.5%
Total equity$305.6M+1,589%
Total assets$330.8M+310%

Cash flow

See full
Operating cash flow-$15.5M+7.6%
Free cash flow-$15.5M+7.6%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$531.62M+228%
Enterprise value$501.68M+257%
P/S7.1×+2.2×

Returns & leverage

See full
Debt / equity0×-0.2×
Current ratio14×+12.4×

FAQ

When did Assembly Biosciences report Q2 2026 earnings?
Assembly Biosciences (ASMB) reported Q2 2026 earnings on August 13, 2026 after market close.
What were Assembly Biosciences's Q2 2026 revenue and EPS?
Assembly Biosciences reported revenue of $13.4M and eps of $-0.20 for Q2 2026.
Did Assembly Biosciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $8.6M by $4.8M. EPS beat the consensus estimate of $-0.72 by $0.52.
How did Assembly Biosciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 38.9% from $9.6M a year earlier and eps grew 85.0% from $-1.33.
Where can I find Assembly Biosciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-349198) and the 10-Q periodic report (0001193125-26-349236) directly on SEC EDGAR. The filing index links above go to sec.gov.